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11were diabetes (41.3%), hypertension (69.4%), hypercholesterolemia (75.7%) and his-
tory of smoking (47.6%). STEMI (3.9%) and NSTEMI (13.1%) were present at baseline.
Lesion characteristics were 3.02  0.64 mm (reference vessel diameter) and 14.6 
6.5 mm (lesion length). Treated vessels were LAD (37.6%), RCA (28.6%), LCX (27.6%)
and others (6.2%). Cypher-ISR (36.7%) was the most common type of DES-ISR fol-
lowed by Taxus-ISR (20.0%), Xience-ISR (20.0%), Promus-ISR (8.1%), Endeavor-ISR
(5.7%) and others (9.5%). ISR patterns were focal (52.9%) and diffuse (47.1%). 9-month
follow-up was available in 90.8% (187/206) of all patients. The duration between DES
implantation and restenosis was 3.0  2.4 years.
The 9-month TLR rate was 7.0% (13/187) whereas incidences of MI and cardiac
death were 4.3% (8/187) and 2.1% (4/187) respectively. The composite MACE rate at 9
months was 10.2% (19/187).
CONCLUSIONS Up to date this is the largest prospective registry in an unselected
patient population with DES-ISR treated with PCB angioplasty. The rates for TLR and
MACE were low and seem to be an attractive alternative treatment option despite the
lack of reimbursement in France.CORONARY: OTHER
CRT-155
Bioﬂow-III an All Comers Registry with a Sirolimus Eluting Stent- One Year Safety
and Performance Results
Johannes Waltenberger,1 Stefan Hoffmann,2 Johannes Brachmann,3
Jan van der Heyden,4 Gert Richardt,5 Ole Fröbert,6 Markus Seige,7 Otmar Pachinger,8
Andrejs Erglis,9 Willem de Wilde10
1Uniklinik Muenster, Muenster, Germany; 2Vivantes Klinikum im Friedrichshain,
Berlin, Germany; 3Klinikum Coburg, Coburg, Germany; 4St. Antonius Ziekenhuis,
Nieuwegein, Netherlands; 5Segeberger Kliniken, Bad Segeberg, Germany;
6Universitetssjukhuset Örebro, Örebro, Sweden; 7Krankenhaus Martha Maria gGmbH,
Halle-Dölau, Germany; 8University Hospital Innsbruck, Innsbruck, Austria; 9Pauls
Stradins Clinical University Hospital, Riga, Latvia; 10Twee Steden Hospital Tilburg,
Tilburg, Netherlands
OBJECTIVE The aim of this registry is to evaluate the clinical performance of a new
generation Sirolimus eluting stent system (Orsiro) in a large patient population in
standard clinical care.
The Orsiro is a unique hybrid solution that combines passive and active compo-
nents. PROBIO passive coating encapsulates the stent and minimizes interaction
between the metal stent and surrounding tissue. BIOlute active coating contains a
highly biocompatible and biodegradable polymer.
METHODS Between August 2011 and March 2012, 1,356 subjects were enrolled
consecutively in this international, multicentric BIOFLOW-III all-comers registry us-
ing the Orsiro Sirolimus eluting stent.
Primary endpoint is Target Lesion Failure (TLF) at twelve months follow-up. Pre-
speciﬁed subgroups were diabetes, small vessels, chronic total occlusion and acute
myocardial infarction. In addition subjects with B2/C lesions, which are known to
have a higher risk for cardiac complications or restenosis have been evaluated.
RESULTS Nine hundred seventy one men (72%) and three hundred eighty ﬁve
women were enrolled at 43 sites in 14 countries. The mean age was 66.1  10.7,
ranging from 29 - 91 years. The majority of subjects presented with hypertension 76%,
hypercholesterolemia 60%, smoker 55%, and diabetes 30%. 48% of all stented vessels
had a diameter 2.75mm, 4% presented with chronic total occlusion. Eleven percent
of the subjects experienced unstable angina, 47% stable angina. Acute MI was seen in
33% of the subjects (NSTEMI 22%, STEMI 11%). The portion of elderly subjects (75
years) is represented by 25%. An unbiased patient population was seen in the registry
with more than 52% type B2/C lesions. Moderate and severe calciﬁcation was
observed in 31%. The Orsiro hybrid stent system demonstrated excellent device
(98.7%) and procedure success (98.2%). In this all-comers setting a TLF rate of 5.1%
was observed within the ﬁrst 12 months. The low TLF rate was also conﬁrmed for the
subgroups: diabetics (7.7%), acute MI (7.2%), small vessel (5.8%), CTO (1.8%) and
complex B2/C lesions (5.1%).
CONCLUSION The results observed in this “real world” population demonstrate a low
TLF rate comparable to other state of the art DES at 6- and 12-months.CORONARY: OTHER
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OBJECTIVES BIOFLOW-II is a randomized controlled study, comparing the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience Prime) at 2 Years in the complete study population
as well as in the diabetic and small vessel subgroups, which are known to have a
higher risk for cardiac complications. Here we present the outcome through the
clinical endpoints Target Lesion Failure (TLF) and Stent Thrombosis (ST).
METHODS A total of N¼452 subjects (62.710.4, 38-80 yrs) were enrolled in the
Intention to Treat population in the BIOFLOW-II study, registered at clinicaltrials.gov
(NCT01356888). All subjects were stratiﬁed for diabetes and then randomly assigned
(2:1) to receive the Orsiro or the Xience Prime stent. The diabetic subgroup accounted
for 28.3% N¼128 (Orsiro N¼84, Xience Prime N¼44) of all subjects. The small vessel
cohort included all subjects with a reference vessel diameter 2.75mm, accounting
for 57.3% N¼259 (Orsiro N¼168, Xience Prime N¼91) of all subjects. Clinical follow up
visits are performed at 1, 6, 12 months and annually up to 5 years after the procedure.
All angiographic images were analyzed by an independent Corelab. All clinical events
were adjudicated by an independent clinical events committee.
RESULTS All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The TLF rate at 24 months was 8.4% for the Orsiro vs. 10.0% for
the Xience Prime in the full cohort, 9.7%vs. 9.1% in the diabetic subgroup and 9.4%
vs. 13.3% for subjects with small vessel lesions. There was no statistical signiﬁcance
between the two study arms in any of the three analyzed populations. No ST
(deﬁnitive, probable or possible) occurred through 24 months in the Orsiro arm.
Conclusion In this RCT the clinical event rates of the Orsiro SES with a biodegradable
polymer were low and comparable to the Xience Prime up to 24 month in all three
analyzed populations.ENDOVASCULAR: PERIPHERAL VASCULAR INTERVENTION
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BACKGROUND Percutaneous transluminal angioplasty has historically been the
standard in minimally invasive treatment of peripheral artery disease (PAD). In iliac
arteries, self-expanding, nitinol stent technology has evolved as an effective treat-
ment of atherosclerotic lesions. BIOFLEX-I evaluates the safety and efﬁcacy of the
Astron stent in the iliac arteries.
METHODS The BIOFLEX-I study was a prospective, multicenter, non-randomized,
single arm, investigational device exemption (IDE) study performed in the United
States, Canada, and Europe. Thirty (30) study centers enrolled 161 evaluable study
subjects for treatment of de novo or restenotic lesions (140mm length) or occlusions
(100mm length) in common and/or external iliac arteries with reference vessel di-
ameters from 6 to 9mm. The primary endpoint was the composite rate of procedure or
stent related major adverse events (MAEs) at 12 months post index procedure. MAEs
were deﬁned as 30-day mortality, clinically-indicated target lesion revascularization
(TLR) and index limb amputation at 12 months. Results were compared to a pre-
speciﬁed performance goal based on prior prospective, multicenter studies utilizing
nitinol-based, self-expanding stents for the treatment of iliac lesions similar to those
in this study. Core laboratories were utilized for independent conﬁrmation of angi-
ography and duplex ultrasound ﬁndings. All site reported MAEs were adjudicated by
an independent Clinical Events Committee.
RESULTS For the BIOFLEX-I study of patients with iliac disease treated with the
Astron stent, the primary endpoint was met. The 12-month composite endpoint of
MAE was 2.1% (3/146) (p<0.001) 95 % CI [0.4%, 5.9%]. The 30 day mortality rate was
0.7% (1/146) 95 % CI [0.0%, 3.8%]. Target lesion revascularization (TLR) rates at 12
months were 1.4% (2/146) 95 % CI [0.2%, 4.5%], and 12-month index limb amputation
was 0.0% (0/146) 95 % CI [0.0%, 2.5%]. The secondary endpoint of primary patency
was 89.8% (115/128) 95 % CI [83.3%, 94.5%] at 12 months.
CONCLUSION The 12-month outcomes of the BIOFLEX-I study for the Astron stent in
iliac indications demonstrate a low MAE rate, high primary patency, and a low rate of
TLR. This supports the safety and efﬁcacy of the self-expanding, nitinol stent for
treatment of atherosclerotic lesions in the iliac arteries.
